Treatment of stage D prostatic carcinoma with megestrol acetate

  title={Treatment of stage D prostatic carcinoma with megestrol acetate},
  author={M. Block and Philip D. Bonomi and K M Anderson and Janet M. Wolter and J. L. Showel and Dennis Pessis and Robert E. Slayton},
  journal={Journal of Surgical Oncology},
Nine previously untreated patients with stage D prostatic carcinoma received megestrol acetate 40 mg orally three times daily. Responses included five partial regressions, two stabilizations, and two progressions. Duration of response ranged from 3 + to 33 + months, with a mean of 11.7 months and a median of 12 months. Three of five patients who had failed prior hormonal therapy remained objectively stable while receiving megestrol acetate. No gastrointestinal toxicity, gynecomastia, fluid… 
11 Citations
Phase II study of megestrol acetate for metastatic carcinoma of the prostate.
Megestrol acetate has only limited efficacy in patients previously treated for prostatic cancer by hormonal manipulation.
Megestrol acetate in the treatment of hormone refractory prostate cancer.
This retrospective study evaluates the efficacy of megestrol acetate in patients with hormone refractory metastatic metastatic adenocarcinoma of the prostate and shows little activity, and cannot recommend megestro acetate as an effective second-line therapy.
Megestrol acetate plus minidose diethylstilbestrol in the treatment of carcinoma of the prostate.
Since megestrol acetate plus minidose DES is equivalent to DES in achieving treatment responses in patients with carcinoma of the prostate, it is a preferable treatment because of its improved side-effect profile.
Phase II trial of hormonal cytoreduction with megestrol and diethylstilbestrol in conjunction with radiotherapy for carcinoma of the prostate: outcome results of RTOG 83-07.
Although DES appears more effective in suppressing testosterone, it is also associated with a higher incidence of drug-related toxicity, which indicates comparable efficacy (using tumor clearance as an end point) of DES and Megestrol.
Hormonal cytoreduction in locally advanced carcinoma of the prostate treated with definitive radiotherapy: preliminary results of RTOG 83-07.
While DES appears more effective in suppressing testosterone it is also associated with a higher incidence of toxicity, and the results of the study indicate comparable efficacy (using tumor clearance as an end-point) of DES and Megestrol.
Systemic treatment for prostate cancer.
  • A. Lyss
  • Medicine
    The American journal of medicine
  • 1987
At the present time, the optimal use of cytotoxic drugs remains undefined, since recently published studies have shown neither that combination chemotherapy is superior to single agents nor that chemo-hormonal therapy produces more favorable results than hormonal treatment alone.
Megestrol acetate: clinical experience.
Megestrol acetate can be considered as an effective medical alternative to surgery for endometrial hyperplasia or benign prostatic hypertrophy, and has the advantage of stimulating appetite and weight gain, a benefit in cancer patients.
Treatment of advanced cancer of the prostate.
The response rates to chemotherapy are disappointing and those who either never respond or relapse after primary treatment may show some response to further hormone therapy but usually require the combination of radiotherapy and analgesia to control their symptoms.
Phase II trial with D‐Trp‐6‐LH‐RH in prostatic carcinoma: Comparison with other hormonal agents
It is suggested that hormonal therapy with LH‐RH agonists can be combined with chemotherapy, the intial response to which might be potentiated by an early and transitory increase in testosterone levels.
II--Cancer cachexia: treatments strategies.
  • D. Gough, S. Heys, O. Eremin
  • Medicine
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • 1996


Megestrol acetate for treatment of advanced carcinoma of the prostate
The results suggest that a staged hormonal approach, using progestin therapy initially, may offer additional palliation in treating patients with metastatic prostatic carcinoma.
Treatment of advanced cancer of prostate with megestrol acetate.
Since megestrol appears to be effective therapy for previously untreated prostatic cancer and since it does not cause gynecoinastia, salt retention, or thromboembolism, it should be studied further as a possible first line drug in the treatment of Stage D prostaticcancer.
Chemotherapy of advanced prostatic cancer. Evaluation of response parameters.
A total of 125 patients with progressing advanced prostatic cancer were entered into a chemotherapy study comparing cyclophosphamide, 5-fluorouracil, and standard therapy, and there were more objective responders to cyclophile than standard therapy whether the hemoglobin was initially normal or low.
Treatment of stage IV carcinoma of the prostate.
Accurate diagnosis and staging of carcinoma of the prostate is essential to rational management of this disease and evidence suggests that low dose estrogen therapy, 1 mg stilbestrol daily, provides the best opportunity for long-term control.
Evidence is presented that significant improvement often occurs in the clinical condition of patients with far advanced cancer of the prostate after they have been subjected to castration and this work provides a new concept of prostatic carcinoma.
Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate
It is demonstrated that a marked rise in acid phosphatase in serum is associated with the appearance or spread of roentgenologically demonstrable skeletal metastases and implies dissemination of the primary tumor and thus is of unfavorable prognostic significance.